Clorox (NYSE:CLX) had its target price hoisted by investment analysts at Wells Fargo & Co from $130.00 to $146.00 in a research note issued on Thursday. The firm currently has a “market perform” rating on the stock. Wells Fargo & Co’s price target points to a potential upside of 1.79% from the company’s previous close.
CLX has been the topic of a number of other research reports. Jefferies Group reaffirmed a “hold” rating and set a $132.00 price target on shares of Clorox in a report on Wednesday, November 1st. Zacks Investment Research cut Clorox from a “hold” rating to a “sell” rating in a report on Wednesday, October 4th. Morgan Stanley dropped their target price on Clorox from $138.00 to $128.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Royal Bank of Canada reissued a “hold” rating and set a $115.00 target price on shares of Clorox in a report on Sunday, October 8th. Finally, BMO Capital Markets reissued a “buy” rating and set a $150.00 target price on shares of Clorox in a report on Thursday, October 5th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $132.05.
Shares of Clorox (NYSE CLX) opened at $143.43 on Thursday. The firm has a market capitalization of $18,680.00, a P/E ratio of 26.32, a PEG ratio of 3.94 and a beta of 0.42. The company has a current ratio of 1.10, a quick ratio of 0.77 and a debt-to-equity ratio of 3.02. Clorox has a twelve month low of $118.41 and a twelve month high of $150.40.
In other Clorox news, SVP Matthew T. Laszlo sold 20,051 shares of Clorox stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $130.46, for a total value of $2,615,853.46. Following the transaction, the senior vice president now owns 10,896 shares in the company, valued at $1,421,492.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Michael R. Costello sold 10,574 shares of Clorox stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $136.01, for a total transaction of $1,438,169.74. Following the completion of the transaction, the senior vice president now owns 34,867 shares in the company, valued at approximately $4,742,260.67. The disclosure for this sale can be found here. 1.00% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the business. Sun Life Financial INC grew its position in Clorox by 10,344.4% in the second quarter. Sun Life Financial INC now owns 940 shares of the company’s stock worth $125,000 after buying an additional 931 shares during the last quarter. Acrospire Investment Management LLC acquired a new position in Clorox in the second quarter worth approximately $133,000. Salem Investment Counselors Inc. grew its position in Clorox by 2.5% in the second quarter. Salem Investment Counselors Inc. now owns 1,256 shares of the company’s stock worth $167,000 after buying an additional 31 shares during the last quarter. Phocas Financial Corp. purchased a new position in Clorox during the 2nd quarter worth approximately $167,000. Finally, Jacobi Capital Management LLC grew its position in Clorox by 0.3% during the 2nd quarter. Jacobi Capital Management LLC now owns 1,286 shares of the company’s stock worth $172,000 after purchasing an additional 4 shares in the last quarter. Hedge funds and other institutional investors own 73.14% of the company’s stock.
Clorox Company Profile
The Clorox Company is a manufacturer and marketer of consumer and professional products. The Company sells its products primarily through mass retail outlets, e-commerce channels, wholesale distributors and medical supply distributors. The Company operates through four segments: Cleaning, Household, Lifestyle and International.
